Inventor
Kerry Benenato
Inventor
Sudbury, MA, US
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C07KPeptides14%
C12NMicroorganisms or enzymes12%
C07DHeterocyclic compounds7%
B82YSpecific uses or applications of nanostructures6%
C07CAcyclic or carbocyclic compounds6%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
C12YEnzymes3%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds2%
PatentTitleYear
11,071,716Combinations of mRNAs encoding immune modulating polypeptides and uses thereof202111,066,355Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents202111,001,861Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1202111,000,573Polynucleotides encoding interleukin-12 (IL12) and uses thereof202110,993,918Polynucleotides encoding citrin for the treatment of Citrullinemia type 2202110,973,917MRNA combination therapy for the treatment of cancer202110,857,105Compounds and compositions for intracellular delivery of therapeutic agents202010,799,463Compounds and compositions for intracellular delivery of agents202010,730,924Polynucleotides encoding relaxin202010,646,549Polynucleotides encoding interleukin-12 (IL12) and uses thereof202010,556,018Compositions and methods for delivery of agents202010,519,455Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease201910,494,636Polynucleotides encoding a-galactosidase A for the treatment of Fabry disease201910,485,885Compositions and methods for delivery of agents201910,442,756Compounds and compositions for intracellular delivery of therapeutic agents201910,406,112Polynucleotides encoding methylmalonyl-CoA mutase201910,406,113Combinations of mRNAs encoding immune modulating polypeptides and uses thereof201910,392,341Compounds and compositions for intracellular delivery of therapeutic agents201910,335,486MRNA combination therapy for the treatment of cancer201910,322,090Combinations of mRNAs encoding immune modulating polypeptides and uses thereof201910,322,091Combinations of mRNAs encoding immune modulating polypeptides and uses thereof201910,285,950Combinations of mRNAs encoding immune modulating polypeptides and uses thereof201910,266,485Compounds and compositions for intracellular delivery of therapeutic agents201910,207,010Compositions and methods for delivery of agents201910,195,156Compounds and compositions for intracellular delivery of agents201910,172,808Combinations of mRNAs encoding immune modulating polypeptides and uses thereof20199,867,888'Compounds and compositions for intracellular delivery of therapeutic agents'20189,868,693'Compounds and compositions for intracellular delivery of therapeutic agents'20189,868,691'Compounds and compositions for intracellular delivery of therapeutic agents'20189,868,692'Compounds and compositions for intracellular delivery of therapeutic agents'2018Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2018–2021Patents assigned to MODERNATX INC (30)· patent assignee history
2018–2021Based in Cambridge, MA, US· patent location history
2019–2021Based in Sudbury, MA, US· patent location history
2020Patents assigned to MORDERNATX INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MODERNATX INC | 30 | 2018–2021 |
| MORDERNATX INC | 1 | 2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| Sudbury, Massachusetts, US | 23 | 2019–2021 |
| Cambridge, Massachusetts, US | 7 | 2018–2021 |